Cian Healthcare Limited has fulfilled its regulatory obligations by submitting the mandatory certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The pharmaceutical company, which operates as an ISO 9001:2015 and WHO GMP certified organization, filed this compliance document with BSE Limited on April 14, 2026.

Regulatory Compliance Details

The certificate was issued by Bigshare Services Private Limited, which serves as the company's Registrar and Share Transfer Agent. The document confirms that all securities received from depository participants for dematerialization up to March 31, 2026, were properly processed and confirmed to the depositories within the stipulated timeframe.

Certificate Confirmation

Bigshare Services Private Limited confirmed several key compliance aspects in their certificate dated April 10, 2026. The registrar verified that securities received for dematerialization were properly accepted or rejected, and that these securities have been listed on the stock exchange where the company's earlier issued securities are already listed.

The certificate also confirms that:

• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• The names of depositories have been substituted in the register of members as registered owners
• All processes were completed within 15 days of receipt of security certificates

Company Information

Cian Healthcare Limited operates with its registered office in Pune, Maharashtra, and maintains a corporate office in New Delhi. The company also operates a manufacturing facility in Uttarakhand. Rachit Malhotra, serving as Company Secretary and Chief Compliance Officer, signed the submission document on behalf of the company.

Regulatory Significance

This certificate submission represents standard regulatory compliance for listed companies under SEBI regulations. The requirement ensures transparency in the dematerialization process and confirms that companies maintain proper records of share transfers and ownership changes through depository participants.

Cian Healthcare Limited has announced receipt of trading approval from BSE Limited for 2,50,00,000 fully paid-up equity shares, marking a crucial step in the company's restructuring process following the NCLT-approved resolution plan. The trading approval, received on March 30, 2026, enables the company's equity shares to be admitted for trading on BSE Limited effective April 2, 2026.

Share Allocation Structure

The approved equity shares carry a face value of INR 10 each and are distributed across two distinct categories of shareholders as per the resolution plan framework.

Resolution Plan Implementation

The trading approval stems from the Hon'ble National Company Law Tribunal (NCLT) order dated December 18, 2025, which approved the resolution plan submitted by the Successful Resolution Applicant, Mr. Pradeep Kumar Jain, under the Insolvency and Bankruptcy Code, 2016. The public shareholders' allocation of 12,50,000 shares was approved during the Resolution Plan Implementation Committee meeting held on January 23, 2026, while the promoters' allocation of 2,37,50,000 shares received approval in the Board of Directors meeting conducted on March 16, 2026.

Regulatory Compliance Framework

The disclosure has been made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company has adhered to provisions outlined in SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026, ensuring comprehensive regulatory compliance throughout the process.

Trading Commencement Details

BSE Limited has confirmed that trading members of the Exchange are authorized to trade in the company's securities effective April 2, 2026. The equity shares bear distinctive numbers ranging from 1 to 25000000, providing clear identification for trading purposes. This development represents the culmination of the corporate restructuring process initiated under the insolvency and bankruptcy proceedings.

Corporate Information

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified company with its registered office located in Pune, Maharashtra, and corporate office in New Delhi. The company maintains manufacturing facilities in Uttarakhand and continues to focus on pharmaceutical operations while navigating the post-resolution phase of its corporate journey.